Ordering
Available Variants5 mg
CHA.58218-5mg
Price
€84.00
Available – Dispatch in 14 days
25 mg
CHA.58218-25mg
Price
€321.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
5 mg | CHA.58218-5mg | €84.00 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
25 mg | CHA.58218-25mg | €321.60 |
≥98% (HPLC), selective inhibitor of the Na+/H+ exchanger subtype 1, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C12H17N3O3S |
|---|---|
| CAS Number | 159138-80-4 |
| Molecular Weight | 283.35 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329825815 |
| NACRES | NA.77 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| Storage Class | 11 - Combustible Solids |
|---|---|
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
Cariporide, with a CAS number of 159138-80-4, is a potent and selective inhibitor of the Na+/H+ exchanger isoform 1 (NHE1). This compound has been extensively studied for its potential therapeutic applications, particularly in the treatment of myocardial ischemia and reperfusion injury. By inhibiting the NHE1 exchanger, cariporide reduces the influx of sodium ions into cardiac myocytes, thereby mitigating the subsequent increase in intracellular calcium levels and the resulting cellular damage. This mechanism of action has been shown to reduce the severity of ischemic injury and improve cardiac function in various preclinical models. As a result, cariporide has been investigated as a potential cardioprotective agent, with its efficacy and safety profile being evaluated in clinical trials to determine its suitability for use in patients with acute coronary syndromes.
